CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

ONCOLOGY Nurse Edition. Vol. 22 No. 8
Pages: 1  2  3  4  5  
Previous Next
 

Care of the Pregnant Patient With Cancer

By Sue Rimes, RN
Clinical Nurse, Outpatient

Jacalyn Gano, RN, OCN, MSW
Manager of Clinical Protocol Administration
Andrea Milbourne, MD
Associate Professor

Department of Gynecological Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

| July 1, 2008

Timing of Treamtment During Gestation

The first trimester of pregnancy, from conception to the end of the 12th week, is the period of organogenesis, when most treatment is contraindicated. The second trimester is from week 13 to the end of week 26, and the third trimester is from the 27th week until delivery. A full-term pregnancy is 40 weeks in duration.

Implantation occurs in the first 2 weeks following conception. If chemotherapy is given at this time, a spontaneous abortion is likely to occur. All major organs and organ systems are formed during the second to eighth week of gestation. The developing embryo is most susceptible to teratogenic effects of antineoplastic agents at this time.[14]

The ideal time for treatment is during the second trimester and early part of the third trimester, during which time the fetus is formed and continues to mature. A fetus is usually considered viable at 24 weeks.[1,2] At this time, survival is possible with neonatal intensive care. Each time the patient is seen, it is important to always document the last menstrual period, the expected date of delivery, and the gestational age, as it is essential to know when the fetus is viable.

It is also important to document the name and contact information of the patient’s obstetrician and/or maternal fetal medicine (MFM) specialist, and the hospital that will be used for delivery, so that the information is readily available in case of an emergency. If a patient is hospitalized between 24–40 weeks’ gestation in a facility with no obstetric or neonatal services, then there must be a plan of action in case the patient shows any signs of premature labor. If the patient is suspected to be in labor, steps should be taken to immediately transport her to a facility equipped with obstetrical care and a neonatal intensive care unit. At our center, we notify the gynecologist on call to assess the patient. If she is in labor, the gynecologist then contacts the nurse manager who coordinates patient transfer.

Figure 3: Management Protocol—Care of pregnant cancer patients at M.D. Anderson Cancer Center. EMR = electronic medical record; MD = medical doctor; MFM = maternal fetal medicine specialist; OB = obstetric; US = ultrasound.

Timing of delivery is crucial for patients receiving chemotherapy during pregnancy, and is based on response to chemotherapy. The last dose should be given before week 34–36, to allow sufficient time for the patient’s blood counts to recover prior to delivery. In spite of this timing, the newborn may also have pantocytopenia at birth, owing to the inability of the immature liver and kidneys to metabolize and eliminate the cytotoxic agents.[14] When early delivery is chosen, the mother receives steroid injections to increase fetal lung functions and limit intracranial bleeds.[15]

For the melanoma patient, it is recommended that the placenta be sent to pathology at the time of delivery, as melanoma can cross the placental barrier.
Breastfeeding is contraindicated if chemotherapy or hormonal therapy are given postpartum, as cytotoxic agents can be excreted in breast milk.[11,15] Post delivery, the nurse can assist the patient in obtaining follow-up appointments with her oncologists to resume therapy.

Pages: 1  2  3  4  5  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





What are you thinking. . .
About this month’s articles/other issues in oncology? Contact: Anne.Landry@cmpmedica.com

 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
CME ACTIVITIES

Current Challenges in Metastatic Breast Cancer:

Patient Management and Treatment Strategies

Interactive Case Challenge Series

 

This series of case presentations (five individual cases) will provide oncologists and other healthcare professionals with strategies for evaluating evidence-based data on the latest treatments in metastatic breast cancer (MBC) and the application of that data into the development of individualized approaches to care, including overcoming resistance, in order to optimize management and outcomes for patients.

 

Go to Activity

 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed
CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy